University of California San Francisco

Brian Shoichet, PhD

Education

Institution Degree Dept or School End Date
University of California, San Francisco Ph.D. Graduate Division (Pharmaceutical Chemistry) 1991

Awards & Honors

Award Conferred By Date
Society for Biomolecular Sciences Accomplishment Award 2011
Topliss Lectureship University of Michigan 2011
Abbott Lectureship Yale University 2009
Swiss Universities 3e Cycle en Chimie (Lausanne, Bern, Friborg, Geneva) 2008
Novartis Chemistry Lecturer (Cambridge, Basel, Vienna, Horsham, Tsukuba, Emeryville) 2006/2007
Astra Lectureship University of Ottawa 2004
Dean’s Award for Teaching Excellence Northwestern University 2001
CAREER Award National Science Foundation 1998/2003
Career Development Award PhRMA Foundation 1997/1999
Damon Runyon-Walter Winchell Cancer Research Fellow 1993/1996

Grants and Funding

  • Development and Testing of New Computational Methods for Ligand Discovery and Mechanism | NIH | 2017-06-01 - 2027-08-31 | Role: Principal Investigator
  • STRUCTURE AND FUNCTION OF MRG-FAMILY RECEPTORS | NIH | 2022-04-01 - 2027-01-31 | Role: Co-Principal Investigator
  • Molecular Details of Psychoactive Drug Actions | NIH | 2017-03-06 - 2026-11-30 | Role: Co-Principal Investigator
  • A Web-Based Automatic Virtual Screening System | NIH | 2004-08-01 - 2025-04-30 | Role: Principal Investigator
  • Degenerative and Dementing Diseases of Aging | NIH | 1981-01-01 - 2025-03-31 | Role: Co-Investigator
  • Illuminating the Druggable GPCR-ome | NIH | 2017-09-15 - 2023-08-31 | Role: Co-Principal Investigator
  • A Specific Mechanism for non-specific inhibition | NIH | 1992-08-01 - 2019-05-31 | Role: Principal Investigator
  • Design and Experimental Testing of New Docking Methods | NIH | 1999-08-01 - 2018-11-30 | Role: Principal Investigator
  • Scalable technologies for illuminating the druggable GPCR-ome | NIH | 2014-08-01 - 2018-04-30 | Role: Co-Principal Investigator
  • Bio-Organic Biomedical Mass Spectrometry Resource | NIH | 1982-03-01 - 2015-05-31 | Role: Co-Investigator
  • Structure, Function and Inhibition of Beta-Lactamases | NIH | 2001-08-01 - 2015-02-28 | Role: Principal Investigator
  • Resource for Biocomputing, Visualization, and Informatics | NIH/NCRR | 1976-06-01 - 2012-09-14 | Role: Co-Investigator
  • Promiscuous and Specific Inhibitors of Cruzain | NIH | 2007-09-01 - 2008-08-31 | Role: Principal Investigator

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Toward a Random Background for Ligand Optimization.
    Xu X, Mailhot O, Correy GJ, Huang XP, Braz J, Shi D, Srinivasan K, Zielinski K, Holota Y, Kuziv Y, Tsoutsouvas C, Levinzon N, Doruk YU, Rachman M, Diolaiti M, Stevens M, Liu F, Holland K, Hübner H, Wang J, Wu Y, Ashworth A, Makriyannis A, Zhang Y, Moroz Y, Gmeiner P, Abel R, Manglik A, Basbaum AI, Roth BL, Fraser JS, Shoichet BK| | PubMed
  2. The Selectivity Implications of Docking Libraries with Greater and Lesser Similarities to Bio-like Molecules.
    Hall BW, Sakamoto K, Huang XP, Irwin JJ, Shoichet BK, Roth BL| | PubMed
  3. Library docking for Cannabinoid-2 Receptor ligands.
    Rachman MM, Iliopoulos-Tsoutsouvas C, Sacco MD, Xu X, Wu CG, Santos E, Glenn IS, Paris L, Cahill MK, Ganapathy S, Tummino TA, Moroz YS, Radchenko DS, Okorie M, Tawfik V, Irwin JJ, Makriyannis A, Skiniotis G, Shoichet BK| | PubMed
  4. Drug-Induced Phospholipidosis as an Artifact in Antiviral Drug Repurposing.
    Glenn IS, Paris L, White AD, Garda VG, Montano M, Khalid MM, Kao AW, Ott M, Shoichet BK| | PubMed
  5. Large Library Docking for Polypharmacology.
    Wu Y, Vigneron S, Braz J, Srinivasan K, Fink EA, Huang XP, Xu X, Huebner H, Kim JY, Wang J, Pfeiffer T, Sakamoto K, Radchenko DS, Rodriguiz RM, Moroz YS, Irwin JJ, Gmeiner P, Billesboelle C, Roth BL, Basbaum AI, Manglik A, Wetsel WC, Shoichet BK| | PubMed
  6. The selectivity implications of docking libraries with greater and lesser similarities to bio-like molecules.
    Hall BW, Sakamoto K, Huang XP, Irwin JJ, Shoichet BK, Roth BL| | PubMed
  7. Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection Models.
    Lizzadro L, Li J, Taha TY, Degotte G, Detomasi TC, Zapatero-Belinchon FJ, Hantz ER, Huang S, Matsui Y, Henderson WR, McCann JT, Montano M, Rosecrans J, Torres Pomares DF, McGovern BL, Diaz-Tapia R, Benjamin J, Gordon ME, Suazo ID, Settineri NS, Diallo A, Krogan NJ, Shoichet BK, Verba KA, Albrecht R, García-Sastre A, White KM, Ott M, Craik CS, Renslo AR| | PubMed
  8. Large scale prospective evaluation of co-folding across 557 Mac1-ligand complexes and three virtual screens.
    Kim J, Correy GJ, Hall BW, Rachman MM, Mailhot O, Togo T, Gonciarz RL, Jaishankar P, Neitz RJ, Hantz ER, Doruk YU, Stevens MGV, Diolaiti ME, Reid R, Gopalkrishnan S, Krogan NJ, Renslo AR, Ashworth A, Shoichet BK, Fraser JS| | PubMed
  9. Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy In Vivo.
    Jaishankar P, Correy GJ, Matsui Y, Togo T, Rachman MM, Stevens MGV, Hantz ER, Zheng J, Diolaiti ME, Montano M, Taha TY, Rosecrans J, Pampel J, Krogan NJ, Shoichet BK, Ashworth A, Ott M, Fraser JS, Renslo AR| | PubMed
  10. Drug-induced phospholipidosis as an artifact in antiviral drug repurposing.
    Glenn IS, Paris L, White AD, Garda VG, Montano M, Khalid MM, Kao AW, Ott M, Shoichet BK| | PubMed